Fucoidan: preventive effect on non -alcoholic fatty liver disease
Do you think fatty liver is a patent for obesity?
NO! NO! NO!
Some people are not fat or drink
Eat less and light, and was found fatty liver
Why is this?
With the acceleration of the rhythm of life, the diverse lifestyle and the popularity of obesity, non-alcoholic fatty liver disease (Nafld) has become the most common chronic liver disease in my country. A study of hepatology: In the year of 1999-2018, th teotal prevalence of non -alcoholic fatty liver disease in China was 29.6%. It is expected that the total number of non -alcoholic fatty liver disease in China will increase to 315 million by 2030.
Non -alcoholic fatty liver disease is not only common in adults, but also has high popularity among children and adolescents.
Non -alcoholic fatty liver 3 stages
Non -alcoholic fatty liver disease can be divided into three stages. The earliest was simple fatty liver. At this stage, there was excessive fat deposition in liver cells, but it has not caused liver cell damage. The second stage is non -alcoholic fatty hepatitis, and hepatocyte damage and inflammatory cell infiltration occur. In the third stage, intrahepatic fibrosis or even cirrhosis.
Harm of non -alcoholic fatty liver
Non -alcoholic fatty liver disease is mostly no clinical symptoms, or the symptoms are mild and lacking specificity, which can be manifested as fatigue, indigestion, mild discomfort in the liver area, hidden pain in the liver area, or sleep disorders. However, asymptomatic does not mean that there is no damage. If NAFLD is not treated in time, it may develop into a disease that threatens life, such as cirrhosis, liver cancer, etc. In addition to causing damage to the liver, NAFLD is also closely related to diabetes, hypertension, metabolic syndrome, arteriosclerotic cardiovascular and cerebrovascular diseases. With the development of economic development and living standards, the increase in food convenience has led to excessive intake of energy and fat, which further increases the risk of NAFLD's disease. Nafld has a serious threat to human health and has a heavy burden on the medical system.
Latest research：
Fucoidan have a certain prevention effect on non -alcoholic fatty liver disease induced by high -fat diet.
Fucoidan is a water -soluble polysaccharide substance that exists in brown algae such as kelp, which is also known as brown seaweed extract. It has a variety of biological activity, including anti -inflammatory, antioxidant, anti -tumor, and blood lipid -lowering effects. Studies have shown that fucoidan combined with fucoxanthin can regulate leptin-lipocidin shaft in fat cells and liver cells, thereby regulating lipids and glycogen metabolism, reducing insulin resistance, and certain alcoholic fatty liver disease Inhibitory effect.
Experimental method: The experimental mice are randomly divided into three groups: control group, high -fat diet group and fucoidan intervention group. The control group fed standard feed, and the other two groups were fed high -fat feed. The control group and the high-fat diet group gives the body salt water daily, and the fucoidan intervention group gives the fucoidan solution. The dose is 100 mg · kg-1 · D-1. Essence After the last time the stomach was administered for 12h, the weight and liver weight of each group of mice were determined, and the liver index was calculated. Use the biochemical kit to detect the variables of gifda corida (ALT), gydaisaminase (AST), total cholesterol (TC), and triglycerides (TG) in each group of mice. The pathological changes of the hepatic tissue of each group of liver tissue were compared with Su Mu Jing-Yichen staining (HE). Meeting inflammatory factor leukocyte-6 (IL-6), tumor necrosis factor (TNF-CI) and oxidation stimulus index C. Citroxytalthane (MDA) content in each group of mice tissue Enzymes (GSH-PX) and super oxide dismissal enzymes (SOD) activity changes.
Experimental results: Compared with the control group, the weight and liver index of the high -fat diet group increased significantly. The content of TG, TC, AST and ALT in liver tissue has increased significantly, and obvious pathological changes have occurred in liver tissue. Along with the increase in inflammatory factor expression and a significant increase in oxidation stress reaction. However, compared with the high -fat diet group mice, the above indicators in the liver organizations accepted by mouse intervention intervention accepted have been significantly improved (P <0.01).
Experimental conclusions: fucoidan can inhibit liver lipid deposition of high -fat diet, and liver inflammation and oxidation stress reaction.
Where to buy high purity fucoidan?
Since the 1960s, Shandong Jiejing Group has paid attention to and studied the nutritional elements in kelp and its applications. In 1997, Jiejing and Ocean University of China jointly cooperated to conduct a study of "Pilot Technology for the production of fucoidan". At the end of 1998, the project was completed and was awarded “Shandong Province Science and Technology Progress Award. So far our fucoidan has been exported to Northa America, Europe and Asia countries and regions.
Important: The functional expression involved in this article comes from the authoritative literature, and the above is only a science of knowledge, and it cannot represent any treatment suggestions.